• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Quotient Limited Announces Appointment of Chief Commercial Officer

    10/5/21 7:45:00 AM ET
    $QGEN
    $QTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QGEN alert in real time by email

    JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally.

    "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels while ensuring we deliver high value-added services to our customers," said Manuel O. Méndez, Chief Executive Officer of Quotient. 

    Mr. El Khoury joins the Company from QIAGEN (NYSE:QGEN), where he served as President, Head of Global Sales of Molecular Diagnostics leading a global team of over 600 people. While there, he drove commercial strategies for major diagnostic portfolios some of which included, infectious disease, transfusion, digital PCR, and COVID-19 testing solutions. He also led expansion strategies across different geographies. Prior to that, he served as Vice President, Commercial Performance at bioMérieux, leading a cross-functional international team. While there, he secured top-line profitability worldwide by driving regional go-to-market strategies and execution plans. Mr. El Khoury also brings international experience in leadership roles at Roche Diagnostics and GE Healthcare.

    "I am very much looking forward to joining the Quotient team and bring value to customers. I will develop all key actions to continue building a best-in-class commercial team and establish key priorities in support of the launch of the MosaiQ solution in transfusion and beyond," said Mr. El Khoury, Chief Commercial Officer of Quotient.

    In connection with his appointment, the Company granted Mr. El Khoury, 300,148 Restricted Stock Units (RSUs) (the Sign-On RSUs) and share options to purchase 235,477 of the Company's ordinary shares (the Sign-On Options). Such grants were issued outside of the Company's 2014 Stock Incentive Plan and were approved by the Company's Board of Directors and the Remuneration Committee of the Board of Directors pursuant to the inducement grant exception under the Nasdaq Rule 563(c)(4), as an inducement that is material to Mr. El Khoury's joining the Company as the Chief Commercial Officer.

    The Sign-On RSUs will vest 50% on the first anniversary of the grant date and the balance will vest pro rata on each of the second and third anniversaries of the grant date. The Sign-On Options will vest in three equal installments on each of the first, second and third anniversaries of the grant date. The vesting of the awards will be subject to Mr. El Khoury's continued service as the Chief Commercial Officer of the Company on each applicable vesting date.

    About Quotient Limited

    Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company's MosaiQ technology to infectious disease diagnostics), current estimates of first quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

    The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

    CONTACT: Investor Relations, [email protected]; +41 22 545 52 26



    Primary Logo

    Get the next $QGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QGEN
    $QTNT

    CompanyDatePrice TargetRatingAnalyst
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    Qiagen N.V.
    $QGEN
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    Qiagen N.V.
    $QGEN
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    Qiagen N.V.
    $QGEN
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    Qiagen N.V.
    $QGEN
    6/27/2024$50.00Peer Perform → Outperform
    Wolfe Research
    Qiagen N.V.
    $QGEN
    12/19/2023$44.00Equal Weight
    Wells Fargo
    Qiagen N.V.
    $QGEN
    12/13/2023Peer Perform
    Wolfe Research
    More analyst ratings

    $QGEN
    $QTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QIAGEN announces plans for transition in leadership of Supervisory Board

      Supervisory Board intends to elect Stephen H. Rusckowski as Chairman following Annual General Meeting on June 26, 2025 Lawrence A. Rosen will not stand for re-election and will step down as Chairman and Supervisory Board member following Annual General Meeting on June 26, 2025 Prof. Dr. Elaine Mardis will also not stand for re-election after serving since 2014 All other current Supervisory Board members will stand for re-election to one-year terms QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Me

      5/7/25 4:20:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

      Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman

      5/7/25 4:05:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

      QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a

      5/7/25 8:45:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Qiagen downgraded by Redburn Atlantic

      Redburn Atlantic downgraded Qiagen from Buy to Neutral

      4/4/25 8:39:19 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Qiagen downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously

      2/19/25 7:04:54 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Qiagen downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00

      1/6/25 8:39:51 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $QTNT
    Financials

    Live finance-specific insights

    See more
    • QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

      Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman

      5/7/25 4:05:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

      QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a

      5/7/25 8:45:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

      QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute

      4/8/25 11:22:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $QTNT
    SEC Filings

    See more
    • SEC Form 6-K filed by Qiagen N.V.

      6-K - QIAGEN N.V. (0001015820) (Filer)

      4/8/25 7:15:09 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Qiagen N.V.

      SCHEDULE 13G - QIAGEN N.V. (0001015820) (Subject)

      2/6/25 9:38:17 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Qiagen N.V.

      6-K - QIAGEN N.V. (0001015820) (Filer)

      1/16/25 5:00:11 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:51:06 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:05:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

      4 - Quotient Ltd (0001596946) (Issuer)

      2/2/23 8:30:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QGEN
    $QTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

      Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

      10/26/22 7:05:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of New Board Member

      JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

      4/26/22 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QGEN
    $QTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Qiagen N.V.

      SC 13G - QIAGEN N.V. (0001015820) (Subject)

      11/8/24 10:52:38 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

      SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

      2/9/24 11:49:03 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

      SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

      12/6/23 12:35:32 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care